EVis Bioscience awarded CHF 311,000 Innosuisse grant to advance RNA therapies for rare genetic diseases
Highly competitive national selection highlights the strong scientific and clinical potential of EVis’s technology
Zurich, Switzerland. EVis Bioscience AG, an ETH Zurich spin-off developing next-generation RNA delivery systems, has been selected by Innosuisse, the Swiss Innovation Agency, to receive CHF 311,000 in non-dilutive funding. This grant, awarded through a highly competitive evaluation process, will support a CHF 461,000 preclinical project carried out in collaboration with the University of Zurich.
The 18-month program focuses on developing new RNA-based therapies for rare genetic diseases, an area where treatment options are extremely limited – and in many cases, non-existent.
“This grant is a strong validation of both the medical need and the scientific quality of our approach. It allows us to accelerate the development of safer, more precise, and more scalable RNA therapies.”
Prof. Elita Montanari, CTO, acting CEO and co-founder of EVis Bioscience
The funding will also enable EVis to expand its scientific team by hiring one full-time postdoctoral researcher and two part-time technicians.
A new generation of non-viral RNA delivery systems
While RNA and gene therapies are progressing rapidly, current delivery systems often remain imprecise, toxic, or difficult to scale.
EVis Bioscience’s NanoVector platform offers an innovative alternative by combining RNA-loaded lipid nanovectors with extracellular vesicles, the body’s natural communication particles. This hybrid system enables:
- precise targeting of specific tissues
- safe delivery of small and large RNAs
- scalable, gentle production under physiological (body-like) conditions
Protected by two international patents, the platform will soon receive the Research Use Only (RUO) label and be ready for market within 8–9 months.
Complementary equity crowdfunding campaign underway
Alongside the Innosuisse grant, EVis Bioscience has launched an equity crowdfunding campaign on Capital Cell – Europe’s leading equity crowdfunding platform for biotechs – to raise €700,000, with more than €400,000 already committed.
This funding complements the non-dilutive support from Innosuisse and will help drive the platform’s commercial launch and upcoming partnership programs.
About Evis Bioscience
Founded in 2024 and headquartered in Zurich, Switzerland, EVis Bioscience is a biotechnology company and spin-off from ETH Zurich dedicated to enabling the next generation of gene and RNA-based therapies. While gene therapies offer transformative potential for rare diseases and genetic disorders, the safe, precise, and scalable delivery of genetic material remains a critical bottleneck.
EVis Bioscience addresses this challenge through EVis NanoVector, a proprietary platform that enables the efficient loading of RNA into extracellular vesicles (EVs), leveraging a natural delivery system with strong potential for precision, safety, and scalability.
The company operates a hybrid business model combining platform licensing, R&D collaborations, and proprietary therapeutic development. EVis provides industry and academic partners with access to its technology through licensing and collaborative research programs, while simultaneously advancing its own therapeutic candidates toward preclinical milestones.
Press contacts
Switzerland – Marta Leonardi
France – Emmanuelle Laplace
